• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Why Have Cervical Cancer Screening Rates Decreased Over the Past Decade in the US?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Individuals in the US receive cervical cancer screening at suboptimal rates but reasons remain unclear 
  • Suk et al. (JAMA Network Open, 2022) estimated changes in USPSTF guideline–concordant cervical cancer screening over time and assessed the reasons women do not receive up-to-date screening by sociodemographic factors 

METHODS: 

  • Pooled population-based cross-sectional study 
  • Population 
    • Women aged 21 to 65 years without previous hysterectomy 
    • Data came from the US National Health Interview Survey from 2005 and 2019 
  • Exposures 
    • Age 
    • Race and ethnicity 
    • Sexual orientation 
    • Rurality of residence 
    • Health insurance type 
  • Study design 
    • USPSTF screening definitions 
      • For 2005: Screening every 3 years for women aged 21 to 65 years 
      • For 2019: Screening every 3 years with a Papanicolaou test alone for women aged 21 to 29 years | Screening every 3 years with a Papanicolaou test alone or every 5 years with high-risk HPV testing or cotesting for women aged 30 to 65 years 
    • Outcomes were compared across sociodemographic factors in 2019 
      • Outcomes in 2005 were compared with 2019 by age group, race and ethnicity, and insurance type  
      • Comparisons were not available for sexual orientation and rurality of residence because of the lack of data from 2005 
  • Primary outcomes 
    • USPSTF guideline–concordant cervical cancer screening rates  
    • Self-reported primary reasons for not receiving up-to-date screening 

RESULTS: 

  • 20,557 women (weighted, 113.1 million women) 
    • Aged 30 to 65 years: 76.3%  
    • Had private insurance: 67.0% 
    • Race/ethnicity 
      • Asian: 6.1% 
      • Hispanic: 17.2% 
      • Non-Hispanic Black: 13.1% 
      • Non-Hispanic White: 61.0% 
      • Other races/ethnicities: 2.7% 
  • In 2019, women aged 21 to 29 years had a significantly higher rate of overdue screening compared to women who were older (P<0.001) 
    • 21 to 29 years old: 29.1%
    • 30 to 65 years old: 21.2% 
  • Significantly higher rates of overdue screening were found among 
    • Those of Asian vs non-Hispanic White race and ethnicity (P=0.01) 
      • Asian: 31.4% 
      • Non-Hispanic White: 20.1% 
    • Those identifying as LGBQ+ vs heterosexual (P<0.001) 
      • LGBT+: 32.0% 
      • Heterosexual: 22.2% 
    • Those living in rural vs urban areas (P=0.04) 
      • Rural: 26.2% 
      • Urban: 22.6% 
    • Those without insurance vs those with private insurance (P<0.001) 
      • Without insurance: 41.7% 
      • Private insurance: 18.1% 
  • The most common reason for not receiving timely screening across all groups was lack of knowledge 
    • In women identifying as LGBT+: 47.2% cited as a reason 
    • In women with Hispanic ethnicity: 64.4% 
  • Previous receipt of HPV vaccine was not a primary reason for not having up-to-date screening (<1% of responses) 
  • From 2005 to 2019, among women aged 30 to 65 years, lack of access decreased significantly as a primary reason for not receiving screening 
    • 2005: 21.8% 
    • 2019: 9.7% 
  • Reasons for not receiving screening that increased significantly over the study period included  
    • Lack of knowledge 
      • 2005: 45.2% 
      • 2019: 54.8% 
    • Not receiving recommendations from health care professionals 
      • 2005: 5.9% 
      • 2019: 12.0% 

CONCLUSION: 

  • Cervical cancer screening rates in the U.S. decreased from 2005 to 2019, and vary widely based on demographic factors 
  • The biggest reported barrier to screening was lack of knowledge and fewer recommendations from health care professionals 
  • Findings regarding populations that were overdue for screening were not unexpected
    • Previous research suggests that changing guidelines put higher risk individuals, such as marginalized populations, at even greater risk for underscreening, supporting the findings in this study
  • The authors state 

…findings also revealed that barriers to screening significantly varied by sociodemographic factors, suggesting cultural adaptation of interventions will be an important factor in the success of efforts to increase cervical cancer screening uptake among priority populations in the US, including women of Asian race and Hispanic ethnicity, women without insurance, women living in rural areas, and/or women identifying as LGBQ+ 

Learn More – Primary Sources: 

Assessment of US Preventive Services Task Force Guideline–Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What is the Most Efficient Method for Cervical Cancer Screening?
What Factors Predict Cervical Cancer Screening in Women Between 45 and 65 Years of Age?
How Many Women Over 65 Meet Criteria for Cervical Cancer Screening Exit?
Does Changing the Frequency of Recommended Cervical Cancer Testing Lead to a Decrease in STI Screening?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site